Danaher Corporation (DHR - Free Report) is in the final stages of completing the acquisition of General Electric Company’s (GE - Free Report) BioPharma business. Yesterday, the conglomerate received a green signal from the U.S. Federal Trade Commission (“FTC”). With this, it completed all requirements for getting antitrust clearances for the buyout.
Notably, Danaher announced the buyout deal in February 2019.
The BioPharma business is part of General Electric’s GE Life Sciences business, which, in turn, is part of the Healthcare segment. The BioPharma business comprises single-use technologies, process chromatography hardware and related consumables, development instrumentation and related consumables, cell culture media and service.
Inside the Headlines
Danaher also noted that the buyout received clearances from the European Commission as well as antitrust authorities of Korea, Brazil, Russia, China, Israel and Japan.
The transaction is anticipated to close on Mar 31, after the fulfillment of conditions mentioned in the purchase agreement.
The buyout has been valued at $21.4 billion. Of the total amount, Danaher will pay roughly $21 billion through cash on hand, funds raised through debts and credit facilities, and proceeds from shares and preferred stock issuances. Also, it will assume certain pension liabilities of General Electric.
Post the completion of the buyout, Danaher will integrate the BioPharma business with its Life Sciences segment. The acquisition is anticipated to strengthen Danaher’s biologics workflow solutions. Earnings accretion of 60 cents per share is anticipated in 2020 (disclosed in January 2020) from the buyout. Previously, Danaher had expected 45-50 cents per share earnings accretion in the first year of the deal completion.
We believe that the above-mentioned transaction is consistent with the company’s policy of acquiring businesses to gain access to new customers, regions and product lines. In 2019, it used $331.3 million for making acquisitions.
Danaher acquired Labcyte Corporation in January 2019. The buyout of Labcyte has been fortifying Danaher’s automation capabilities.
Zacks Rank, Price Performance and Estimate Trend
With a market capitalization of $89.2 billion, Danaher currently carries a Zacks Rank #3 (Hold). The company is poised to benefit from product innovation, Danaher Business System, shareholder-friendly policies and inorganic initiatives. However, forex woes, high costs and huge debts remain concerning.
The company’s share price has decreased 19% in the past three months compared with the 32.7% fall recorded by the industry.
In the past 30 days, the Zacks Consensus Estimate for its earnings has been lowered by 2.2% to $5.42 for 2020 and 1.1% to $6.21 for 2021.
Danaher Corporation Price and Consensus